Abbott's Emerging Markets Strategy Gets A Bump With Piramal Buy
NEW DELHI - Abbott is set to become India's largest pharmaceutical company after it announced a $3.72 billion deal to acquire the domestic formulations business of Mumbai-based Piramal Healthcare May 21
You may also be interested in...
In 2012, Pfizer’s Deal-Makers Seek Strategic Fit, Financial Discipline, Collaborative Risk-Sharing
The Big Pharma has the global scale and reach it needs, but will fill in gaps with deals in which it can add “a lot of” scientific value and “incremental” commercial value, says Pfizer’s EVP-Business Development Kristin Peck.
Abbott Shaves U.S. Pharma Costs With Restructuring
Abbott plans to eliminate 1,900 positions, mainly within commercial and manufacturing, in a restructuring that will yield pre-tax savings of $200 million.
More Deal Of The Year Nominees
It's time for The IN VIVO Blog's Third Annual Deal of the Year competition. This year, awards will be presented in three categories to highlight the most interesting and creative deal making solutions of 2010.